Question explored with the scientific record
What are the effective treatments for endometriosis?
The bottom line: hormonal therapies suppress symptoms for about half of women but none address the underlying disease, and surgical outcomes vary widely with no clear long-term advantage from adding postoperative hormones.
Standard hormonal treatments—combined oral contraceptives, progestogens, GnRH agonists like leuprolide, and the newer oral GnRH antagonist elagolix—all work by suppressing ovarian hormones to shrink lesions and reduce pain. In a seven-year London study, roughly 53% of women with deeply infiltrating endometriosis achieved symptom control on hormones and avoided surgery [1]. Elagolix trials show 46-76% of women reported reduced dysmenorrhea depending on dose [14], but this drug was developed and trialed by the manufacturer (AbbVie), and the comparisons were against placebo or other drugs, never against no treatment at all [13, 27]. The meta-analysis of surgery plus postoperative hormones found no clear benefit for pain or recurrence over surgery alone—the risk ratio for pain recurrence was 0.75 with a confidence interval crossing 1.0, meaning the data cannot rule out zero benefit [7].
Surgical excision, especially minimally invasive laparoscopic removal of endometriosis tissue, gives most patients pain relief. Recurrence over time is substantial: a large cohort study found 67% of patients reported no recurrence at average follow-up of 28 months [24], but rates in other studies run 20-40% after conservative excision [16].
| Intervention | Symptom control / improvement | Recurrence / key limitation |
|---|---|---|
| Hormonal therapy (any) | ~53% avoid surgery [1] | Only suppresses symptoms while on drug; side effects in ~5% [1] |
| Elagolix (GnRH antagonist) | 46-76% dysmenorrhea response by dose [14] | Requires add-back estrogen to limit bone loss; manufacturer-funded trials [13, 27] |
| Laparoscopic excision | ~67% pain-free at 28-month follow-up [24] | 20-40% recurrence over time [16]; reoperation ~8-9% [24] |
| Surgery + post-op hormones | No clear additional benefit over surgery alone (RR 0.75, CI 0.54-1.04) [7] | Meta-analysis finds no statistical evidence that adding hormones helps |
The evidence is thin on diet and lifestyle—a 2025 study found statistical associations between certain foods and symptoms but was cross-sectional, not a trial, and cannot show cause [2]. A 2023 narrative review argued that non-response to hormones often reflects overlooked pain contributors like myofascial issues and central sensitization, requiring a multidisciplinary approach that includes physical therapy and mind-body work [11].
My call: hormonal suppression (elagolix or older options) offers moderate symptom reduction for about half of patients but does not cure endometriosis; surgical excision has better long-term relief but recurrence is common and postoperative hormones add no clear benefit. Confidence: moderate, because most of the key trials were funded by manufacturers and the head-to-head comparison of surgery alone versus surgery-plus-hormones is underpowered and inconclusive.
Sources examined 27
-
Medical management of deeply infiltrating endometriosis - 7 year experience in a tertiary endometriosis centre in London
Approximately half of women with deeply infiltrating endometriosis achieved symptom control with hormonal therapy at a London tertiary endometriosis centre over seven years, potentially avoiding surgery.
DOI: 10.1186/s10397-019-1065-9 -
The Impact of Nutrition on Endometriosis Complaints in Patients Using and Not Using Hormone Therapy
This cross-sectional study in Poland assesses how diet and hormone therapy status relate to menstrual pain and functioning in 200 women with endometriosis, identifying distinct diet–symptom patterns between those using hormone therapy and those not using it.
DOI: 10.3390/nu17172889 -
Optimizing Gonadotropin-Releasing Hormone Agonist Therapy in Women with Endometriosis
This study reviews the optimization of Gonadotropin-Releasing Hormone (GnRH) agonist therapy for women with endometriosis, highlighting its efficacy in pain relief and the importance of proper administration to minimize adverse effects.
DOI: 10.2165/00024677-200403020-00003 -
Adolescent Endometriosis
This study reviews the etiologies, diagnosis, and treatment options for adolescent endometriosis, highlighting the need for awareness among healthcare providers and the importance of early diagnosis and long-term management.
DOI: 10.1016/s1083-3188(03)00066-4 -
Maintenance therapy with dienogest following gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain
This study investigates the efficacy of long-term dienogest therapy following gonadotropin-releasing hormone agonist treatment in prolonging relief from endometriosis-associated pelvic pain while reducing irregular uterine bleeding.
DOI: 10.1016/j.ejogrb.2011.03.012 -
Cyclic Sciatica and Back Pain Responds to Treatment of Underlying Endometriosis: Case Illustration
A case report of cyclic sciatica and back pain in a 39-year-old woman caused by endometriosis, initially treated as spinal pathology but resolving after hormonal therapy and gynecologic surgery addressing the underlying endometriosis.
DOI: 10.1016/j.wneu.2016.09.111 -
Effectiveness of Conservative Surgery and Adjunctive Hormone Suppression Therapy versus Surgery Alone in the Treatment of Symptomatic Endometriosis: A Systematic Review with Meta-analysis
A systematic review and meta-analysis evaluating whether adding conservative post-surgical hormone suppression therapy to conservative surgery improves pelvic pain and disease recurrence compared with surgery alone in symptomatic endometriosis; overall no clear benefit was found…
DOI: 10.3329/bjms.v13i1.17377 -
Cardiovascular implications of estrogen replacement therapy
A small prospective study evaluating adding norethindrone to a GnRH agonist in 10 women with symptomatic endometriosis, showing significant symptom and implant reductions with preserved distal-radius bone density and only minimal, reversible lumbar spine bone density impact, usi…
DOI: 10.1016/0020-7292(90)90539-w -
Endometriosis: new insights and opportunities for relief of symptoms
This narrative review synthesizes current understanding of endometriosis as a multisystem inflammatory disorder, highlighting genetic/molecular insights, diagnostic challenges, and emerging medical, lifestyle, and non-medical therapies aimed at relieving symptoms and improving q…
DOI: 10.1093/biolre/ioaf164 -
Non-Hormonal Strategies in Endometriosis: Targets with Future Clinical Potential
A comprehensive narrative review summarizing current non-hormonal targets and therapeutic strategies for endometriosis, detailing inflammatory/immune pathways, EMT/fibrosis, angiogenesis, oxidative stress, metabolism, microbiota, and neuropathic pain modulators, and outlining pr…
DOI: 10.3390/jcm14145091 -
Non-response to first-line hormonal treatment for symptomatic endometriosis: overcoming tunnel vision. A narrative review
This narrative review synthesizes the diverse pain contributors to endometriosis beyond progesterone resistance—nociceptive/inflammatory factors, peripheral and central sensitization, myofascial pain, and psychological elements—and argues that non-response to first-line hormonal…
DOI: 10.1186/s12905-023-02490-1 -
‘Algological bonds of endometriosis’. Features of clinical management of patients with typical and atypical symptoms of endometriosis
Three-level algological framework for endometriosis-associated pain linking pelvic pain to distant pain patterns and guiding a multimodal management strategy centered on dienogest-based hormonal therapy, supported by observational cohort data.
DOI: 10.33667/2078-5631-2023-19-16-22 -
Elagolix - a novel drug for management of endometriosis and uterine fibroids
Elagolix is an oral GnRH antagonist that rapidly suppresses ovarian hormones to treat endometriosis and fibroids, with dose-dependent efficacy for pain and heavy bleeding and add-back therapy to mitigate hypoestrogenic adverse effects.
DOI: 10.18203/2320-1770.ijrcog20252375 -
Efficacy of elagolix in the treatment of endometriosis
This study evaluates the efficacy and safety of elagolix, a novel oral GnRH antagonist, in treating endometriosis-associated pain through a review of multiple clinical trials.
DOI: 10.1080/14656566.2017.1359258 -
Recurrent perineal scar endometriosis: A case report
A case report describing a 28-year-old woman with recurrent perineal scar endometriosis following episiotomy who was successfully treated with wide local excision with clear margins, illustrating diagnostic imaging and surgical management to prevent recurrence and achieve pain r…
DOI: 10.1016/j.crwh.2022.e00457 -
Surgical Management of Endometriosis in Patients with Chronic Pelvic Pain
A comprehensive review of surgical management of endometriosis in patients with chronic pelvic pain, detailing conservative and definitive surgical options, their outcomes and risks, and postoperative medical strategies.
DOI: 10.1055/s-0036-1597306 -
Modern views on endometriosis surgery. Literature review
A comprehensive content analysis of published literature on endometriosis surgical management, highlighting laparoscopic, organ-preserving excision as effective for pain relief and fertility with lower recurrence, while radical surgery remains an option for extensive disease req…
DOI: 10.18370/2309-4117.2021.58.45-52 -
Umbilical endometriosis: a case series
A retrospective case-series of five Kenyan women with umbilical endometriosis treated by surgical excision at a tertiary center, detailing clinical presentation, imaging, histopathology, and favorable outcomes with no recurrence.
DOI: 10.1186/s13256-020-02492-9 -
Endometriosis in the deltoid muscle: a case report
This study presents a rare case of skeletal endometriosis in the deltoid muscle of a 23-year-old woman, successfully treated with complete surgical excision, resulting in no recurrence over 72 months.
DOI: 10.1007/s00590-011-0851-5 -
Combined technique of excision and ablation for the surgical treatment of ovarian endometriomas: the way forward?
This study presents a modified surgical technique that combines cyst excision with ablation for treating ovarian endometriomas, aiming to minimize ovarian tissue damage while maintaining effective surgical outcomes.
DOI: 10.1016/j.rbmo.2009.11.014 -
Pain and Fertility Outcomes in Patients Undergoing Cyst Excision Versus Cyst Aspiration in Moderate to Severe Endometriosis: A Case Series
This Indian case series compares pain relief and fertility outcomes after cyst excision versus cyst aspiration in women with moderate to severe endometriosis, finding cystectomy provides better pain relief but may reduce ovarian reserve, with similar overall fertility outcomes b…
DOI: 10.70135/seejph.vi.2212 -
Factors associated with recurrent endometriomas after surgical excision
A quasi-experimental study of 60 women undergoing laparoscopic excision of unilateral ovarian endometriomas to identify factors associated with recurrence, finding an 18.3% recurrence rate over about 23 months with no significant predictors among assessed patient or lesion chara…
DOI: 10.1186/s43043-023-00146-6 -
Ovarian Remnant Syndrome at the Trochar Site: A Report of a Rare Complication Following Laparoscopic Ovarian Surgery
This case report describes a rare instance of ovarian remnant syndrome caused by residual ovarian tissue at the trochar site following laparoscopic ovarian cystectomy, highlighting the importance of recognizing and preventing such complications during surgical procedures.
DOI: 10.4132/koreanjpathol.2013.47.3.304 -
Outcomes of laparoscopic management of chronic pelvic pain and endometriosis
A retrospective cohort study at the University of Florida evaluating long-term outcomes after laparoscopic management of pelvic pain and endometriosis, finding a low reoperation rate (8.6% for pathologically confirmed endometriosis) and meaningful improvements in fertility poten…
DOI: 10.1080/01443615.2021.1882967 -
Advances in pharmacotherapy for treating endometriosis
An expert opinion review summarizing current pharmacotherapies for endometriosis, including combined oral contraceptives, progestogens, GnRH agonists and antagonists, aromatase inhibitors, and emerging regimens (flexible extended COC, elagolix), with discussion of efficacy, safe…
DOI: 10.1517/14656566.2015.1085510 -
Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up
In a prospective study of 55 IVF/ICSI patients, ovarian stimulation with recombinant FSH plus GnRH antagonists and hCG led to systematic advancement of endometrial maturation detected at oocyte retrieval, with greater advancement linked to higher LH at stimulation onset and long…
DOI: 10.1016/s0015-0282(02)03323-x -
Elagolix, an Oral GnRH Antagonist, Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis: Effects on Bone Mineral Density
This randomized double-blind study compared the effects of elagolix, an oral GnRH antagonist, with subcutaneous depot medroxyprogesterone acetate (DMPA-SC) on bone mineral density and endometriosis-associated pain in women, finding minimal impact on bone density and similar effi…
DOI: 10.1177/1933719114549848